Laurence Jay Korn Net Worth

The estimated Net Worth of Laurence Jay Korn is at least $911 Millón dollars as of 29 November 2006. Laurence Korn owns over 20,000 units of PDL Biopharma Inc stock worth over $876,899,868 and over the last 21 years Laurence sold PDLI stock worth over $33,974,700.

Laurence Korn PDLI stock SEC Form 4 insiders trading

Laurence has made over 55 trades of the PDL Biopharma Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Laurence exercised 20,000 units of PDLI stock worth $218,000 on 29 November 2006.

The largest trade Laurence's ever made was selling 389,390 units of PDL Biopharma Inc stock on 3 August 2005 worth over $10,264,320. On average, Laurence trades about 29,475 units every 15 days since 2003. As of 29 November 2006 Laurence still owns at least 243,178 units of PDL Biopharma Inc stock.

You can see the complete history of Laurence Korn stock trades at the bottom of the page.

What's Laurence Korn's mailing address?

Laurence's mailing address filed with the SEC is , , , , .

Insiders trading at PDL Biopharma Inc

Over the last 22 years, insiders at PDL Biopharma Inc have traded over $45,966,964 worth of PDL Biopharma Inc stock and bought 12,693,393 units worth $32,804,545 . The most active insiders traders include Point Capital L.P.O'shea Ro..., Faheem Hasnain y Laurence Jay Korn. On average, PDL Biopharma Inc executives and independent directors trade stock every 24 days with the average trade being worth of $245,074,578. The most recent stock trade was executed by Point Capital L.P.O'shea Ro... on 1 February 2021, trading 187,061 units of PDLI stock currently worth $383,475.

What does PDL Biopharma Inc do?

Complete history of Laurence Korn stock trades at PDL Biopharma Inc

PDL Biopharma Inc executives and stock owners

PDL Biopharma Inc executives and other stock owners filed with the SEC include:

• Dominique Monnet,
  President, Chief Executive Officer, Director
• Christopher Stone,
  Vice President, General Counsel, Secretary
• Edward Imbrogno,
  Chief Financial Officer, Chief Accounting Officer, Vice President - Finance
• John McLaughlin,
  Director
• David Gryska,
  Independent Director
• Elizabeth O'Farrell,
  Chairperson of the Board
• Natasha Hernday,
  Independent Director
• Alan Bazaar,
  Independent Director
• Danny J Jr. Hart,
  Assoc Genl Counsel/Asst Sec
• Samuel R Saks,
  Director
• Jody S Lindell,
  Director
• Paul R Edick,
  Director
• Harold E Selick,
  Director
• Paul W Sandman,
  Director
• Peter S Garcia,
  Vice President, CFO
• Steffen Pietzke,
  Controller and CAO
• Shlomo Yanai,
  Director
• Jill M. Jene,
  VP, Business Development
• Christine R Larson,
  VP & Chief Financial Officer
• Joseph Iii Klein,
  Director
• Karen J Wilson,
  VP of Finance & PAO
• Mark Anthony Mc Camish,
  SVP & CMO
• Brett L Schmidli,
  SVP, Technical Operations
• Gary A Lyons,
  Director
• Andrew Guggenhime,
  SVP & Chief Financial Officer
• Faheem Hasnain,
  President & CEO
• Francis Willard Sarena,
  Exec Dir/Chief Legal Off/Secy
• Herb Cross,
  Corp Controller/Prin Acctg Off
• Richard /Ca/ Murray,
  Sr. VP & CSO
• Steven E Benner,
  SVP and Chief Medical Officer
• Bradford S Goodwin,
  Director
• Laurence Jay Korn,
  Chairman of the Board
• Karen A Dawes,
  Director
• Jaisim Shah,
  Vice President, Marketing
• Jon S Saxe,
  Director
• L Patrick Gage,
  Director
• Glen Y Sato,
  SVP and CFO
• Cynthia Lynn Shumate,
  VP Legal Affrs, Secy & CCO
• Cary L Queen,
  Senior Vice President
• Peter H Calcott,
  VP, Quality & Compliance
• Laurie C Torres,
  VP, Human Resources
• David Iwanicki,
  VP, Sales & Sales Operations
• Mark Mcdade,
  Chief Executive Officer
• Robert Michael Ii Savel,
  SVP Technical Operations
• Samuel Broder,
  Director
• George Jue,
  VP, Fin & Corp. Controller
• Max Link,
  Director
• Sergio Garcia Rodriguez,
  VP, Legal and General Counsel
• Lyn D Olson,
  VP, Quality and Compliance
• Douglas O Ebersole,
  SVP, Legal & Corp Development
• George M Gould,
  Director
• Jurgen Drews,
  Director
• Behrooz Najafi,
  V.P. IS and Corporate Services
• Corine Klingbell,
  VP, Preclinical Development
• William R Benjamin,
  VP, Research & Clinical Tech
• Frances G Charlson,
  VP, Human Resources
• Patrick M Caldwell,
  VP, Finance and Controller
• Mark P Backer,
  VP, Technical Development
• David Montez,
  Controller and CAO
• Fred Frank,
  Director
• Bruce Tomlinson,
  Chief Financial Officer
• Caroline J Krumel,
  Vice President of Finance
• Point Capital L.P.O'shea Ro...,